These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1159 related items for PubMed ID: 15334157

  • 21. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 22. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D, Sobieszczańska M, Kopka L, Marciniak W, Zawadzka-Bartczak E, Bak A, Popielewicz-Kautz A, Korzeniowska J, Janczak J, Adamus J.
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [Abstract] [Full Text] [Related]

  • 23. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL, Blazing MA, Saxena S, Guyton JR.
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am Heart J; 2009 Jan; 157(1):195-203. PubMed ID: 19081418
    [Abstract] [Full Text] [Related]

  • 25. [The effects of simvastatin combined with different antioxidant vitamin regimens on serum lipid profile in patients with low HDL cholesterol levels].
    Pirat B, Korkmaz ME, Eroğlu S, Tayfun E, Yildirir A, Uluçam M, Ozin B, Müderrisoğlu H.
    Anadolu Kardiyol Derg; 2004 Dec; 4(4):318-22. PubMed ID: 15590360
    [Abstract] [Full Text] [Related]

  • 26. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [Abstract] [Full Text] [Related]

  • 27. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 28. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL.
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [Abstract] [Full Text] [Related]

  • 29. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 30. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 31. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 10; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 32. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Sep 10; 11(2):247-57. PubMed ID: 2736571
    [Abstract] [Full Text] [Related]

  • 33. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 10; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 34. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 10; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 35. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM.
    Circulation; 2003 Dec 02; 108(22):2751-6. PubMed ID: 14638544
    [Abstract] [Full Text] [Related]

  • 36. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
    Sheu WH, Jeng CY, Lee WJ, Lin SY, Pei D, Chen YT.
    Metabolism; 2001 Mar 02; 50(3):355-9. PubMed ID: 11230791
    [Abstract] [Full Text] [Related]

  • 37. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E, Ezetimibe Study Group.
    J Womens Health (Larchmt); 2004 Dec 02; 13(10):1101-7. PubMed ID: 15650343
    [Abstract] [Full Text] [Related]

  • 38. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P.
    Int J Clin Pract; 2009 Apr 02; 63(4):547-59. PubMed ID: 19222610
    [Abstract] [Full Text] [Related]

  • 39. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R, Marasi G, Vanasia A, Zoppi A, Lusardi P, Preti P.
    Int J Clin Pharmacol Ther; 1997 Feb 02; 35(2):61-4. PubMed ID: 9147709
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B, Jeamanukulkit N, Piamsomboon C, Chawantanpipat C, Khanacharoen I.
    J Med Assoc Thai; 2004 Nov 02; 87(11):1281-5. PubMed ID: 15825700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.